Document Detail


Antithrombin III concentrates--are they clinically useful?
MedLine Citation:
PMID:  7667814     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment with AT III concentrates is a good example for the discrepancy between the optimistic expectations based on theoretical considerations or animal experiments and the result of clinical studies. 15 years after the introduction into clinical practice, a benefit for patients treated with AT III concentrates has not been proven. In hereditary antithrombin III deficiency, randomized clinical trials are completely lacking and only few and small sized randomized studies were performed in patients with acquired AT III deficiency. In none of these trials, a significant clinical benefit with regard to reduction of morbidity or mortality was detectable. Based on the published data, one can state that AT III concentrates may be beneficial in some special clinical situations in patients with hereditary antithrombin III deficiency (such as delivery, acute serious thromboembolic complications and postoperative thromboprophylaxis). In acquired AT III deficiency, there is no proven indication for the use of AT III concentrates.
Authors:
K Lechner; P A Kyrle
Related Documents :
7284544 - Clinical trials:randomization before consent.
15495114 - Antibiotic regimens for suspected early neonatal sepsis.
15106144 - Local versus general anaesthesia for carotid endarterectomy.
15495034 - Thrombolysis for acute deep vein thrombosis.
24200124 - The performance of matrices in daily clinical practice to predict rapid radiologic prog...
9708654 - Influence of the preoperative signal-averaged electrocardiogram on left ventricular fun...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  73     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  1995 Mar 
Date Detail:
Created Date:  1995-10-11     Completed Date:  1995-10-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  340-8     Citation Subset:  IM    
Affiliation:
Department of Medicine I, University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antithrombin III / isolation & purification,  pharmacokinetics,  therapeutic use*
Antithrombin III Deficiency
Asparaginase / adverse effects
Clinical Trials as Topic
Female
Genetic Predisposition to Disease
Humans
Infant, Newborn
Kidney Diseases / metabolism,  therapy
Liver Diseases / metabolism,  therapy
Postoperative Complications / prevention & control
Pregnancy
Pregnancy Complications, Hematologic / therapy
Randomized Controlled Trials as Topic
Safety
Shock, Septic / therapy
Thromboembolism / genetics,  prevention & control*
Chemical
Reg. No./Substance:
9000-94-6/Antithrombin III; EC 3.5.1.1/Asparaginase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone in adults. An elixir of youth?
Next Document:  Fibrin polymerization defect in HIV-infected patients--evidence for a critical role of albumin in th...